Skip to content

Home page Seeking Alpha - Power to Investors

About Premium
Explore Alpha Picks
NEW Virtual Analyst Report
FREE Newsletters

Stock Analysis
Market News
Market Data
Dividends
ETFs
Earnings
Education
Podcasts
Videos

Investing Groups

Explore Investing Groups

Portfolios

Create Portfolio+
Portfolio Health Check
About Portfolio

Find & Compare

Stock Screener
ETF Screener
Comparisons

Subscriptions

Alpha Picks
Premium & Pro
Group Subscriptions

Search field

Entering text into the input field will update the search result below

Entering text into the input field will update the search result below

Search for Symbols, analysts, keywords

Create a free Seeking Alpha account to access breaking news and valuable research tools »

HEALTHCARE, BIOTECH & PHARMACEUTICAL STOCK NEWS AND ANALYSIS

ANALYSIS

PepGen: Moving To "Hold" Rating On Best Mean Splicing Correction In DM1 Testing

Yesterday, 5:50 PM

Terry Chrisomalis

Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds

Yesterday, 2:02 PM

Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core

Yesterday, 1:38 PM

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Yesterday, 1:00 PM

Market Starting To Embrace The 'New' Regeneron

Yesterday, 12:01 PM

ONeil Trader 3 Comments

Organon: Critical Assessment Of The Audit Committee Investigation Results

Yesterday, 11:19 AM

Dividend and Value Investor 12 Comments

National HealthCare Does Not Flinch During Lease Negotiations

Yesterday, 10:44 AM

AirSculpt Technologies: Upgrading To Buy On Improving Fundamentals

Yesterday, 9:56 AM

Individual Trader 1 Comments

Janux Therapeutics: The Rumor Mill Spins Up Again

Yesterday, 9:55 AM

Galzus Research

Clover Health: Clinical Excellence To Fuel SaaS Growth Beyond The Star Downgrade

Yesterday, 7:30 AM

Ahmed Abdelazim 2 Comments

Hydreight Technologies: Beginning Of A Powerful Revenue Acceleration Phase

Yesterday, 5:53 AM

Deep Sail Capital 1 Comments

After A 50% Decline, Coloplast Might Finally Be Worth Buying

Yesterday, 5:40 AM

Daniel Schönberger 1 Comments

Twist Bioscience: Strong Momentum But Profitability Pending - Why I Hold

Yesterday, 4:32 AM

Gamu Dave Innocent Pasi

Dynavax Technologies Trading At Fair Value

Yesterday, 2:11 AM

Out of Ignorance 1 Comments

Catalyst Pharmaceuticals: Cash Rich, But Running Out Of Catalysts

Yesterday, 1:24 AM

SiliconBytes Insights 3 Comments

UnitedHealth: Strong Long-Term Fundamentals, But Risks Also Exist

Yesterday, 12:36 AM

Arcutis' Q3 Earnings: Increased Foam Share, Better GTN, And Clear 2026 Guide Made Share Rally

Tue, Oct. 28

Stephen Ayers 1 Comments

ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates

Tue, Oct. 28

Just the Facts Maam 4 Comments

Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio

Tue, Oct. 28

Terry Chrisomalis

UnitedHealth Group: The Easy Money Is Gone, But It's Still A Buy After Q3

Tue, Oct. 28

Kenio Fontes 3 Comments

Viking Therapeutics: A Look At The Catalysts Ahead

Tue, Oct. 28

Biotech Beast 4 Comments

Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade)

Tue, Oct. 28

The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products

Tue, Oct. 28

Paul Franke 90 Comments

uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)

Tue, Oct. 28

Stephen Ayers 1 Comments

You Can Spell UnitedHealth Without AI

Tue, Oct. 28

The Techie 4 Comments

UnitedHealth: Great News, Finally

Tue, Oct. 28

Jonathan Weber 6 Comments

Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings

Tue, Oct. 28

Robert J. Lake 2 Comments

ETHZilla: Discounted To NAV And Finding Its Foothold In The Ethereum Ecosystem

Tue, Oct. 28

Mandela Amoussou 6 Comments

AbbVie: Deep Discount Before Earnings

Tue, Oct. 28

Dair Sansyzbayev 16 Comments

UnitedHealth: Nothing Is Over

Tue, Oct. 28

Quad 7 Capital 27 Comments

UnitedHealth Q3: The Falling Knife Has Finally Stopped Falling

Tue, Oct. 28

Julia Ostian 25 Comments

UnitedHealth Group: Third Quarter Was Better Than Expected, But Still Not Good

Tue, Oct. 28

YR Research 13 Comments

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

Tue, Oct. 28

The Value Investor

With Adverum, Eli Lilly Made A Small Bet That Could Pay Off Big

Tue, Oct. 28

Daniel Jones 5 Comments

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating

Mon, Oct. 27

Terry Chrisomalis

Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats

Mon, Oct. 27

Edmund Ingham 1 Comments

Harmony Biosciences: Performing Commercially But Competition Afoot

Mon, Oct. 27

CVS Health: Slow And Steady Wins The Healthcare Race

Mon, Oct. 27

The J Thesis 3 Comments

InMode: Discounted Valuation And Strong Fundamentals Make It A Buy

Mon, Oct. 27

Gamu Dave Innocent Pasi

Novartis' Avidity Deal: Growth Accretive, Multiple Gated By Execution

Mon, Oct. 27

Stephen Ayers 2 Comments

12 3 4 5 Next »

Sharpen Your Strategy With Timely Research

From stock ideas and sector analysis to earnings, M&A, and macro trends - get the insights you need to make smarter investing decisions.

Already a member?

By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy

or

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.